Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CD4^LVFOXP3

Phase 1Biologic

BBacchetta, Rosa, MD

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

IPEXRecruiting

IPEXPhase 1

Recruiting

Timeline

Expected Milestones

Q1 2037

Phase 1Recruiting

IPEX

NCT05241444

Clinical

Trials by Indication[1]

IPEX1 trial

CD4^LVFOXP3 in Participants With IPEX

Recruiting·—·Phase 1·NCT05241444·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CD4^LVFOXP3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD4^LVFOXP3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD4^LVFOXP3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bacchetta, Rosa, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: BBacchetta, Rosa, MD

Related News